Genomic Profiling

Objectives

The major limitation for the use of genetically engineered cells in the clinic is the safety concern. Tumorigenicity from reprogrammed pluripotent stem and/or genome edited cells remains an unsolved concern for clinical application. It will be important to reliably identify intrachromosomal and interchromosomal genomic changes as well as epigenomic changes with high sensitivity to exclude the risk of oncogenesis, to guarantee safety of cell products and to ensure long-term beneficial effects for the patient.